Tegafur is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Zekuan Xu (1) and Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1). Registered phase: Phase 2. Conditions studied include Gastric Cancer; Esophagogastric Junction Adenocarcinoma; Immunotherapy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗) Gastric Cancer, Esophagogastric Junction Adenocarcinoma |
Phase 2 | Recruiting |
| NCT07165847 | Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) (ClinicalTrials.gov ↗) Immunotherapy, Gastric Cancer (GC), Radiotherapy |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastric Cancer | 1 |
| Esophagogastric Junction Adenocarcinoma | 1 |
| Immunotherapy | 1 |
| Gastric Cancer (GC) | 1 |
| Radiotherapy | 1 |
| Neoadjuvant Therapy | 1 |
| Lead sponsor | Trials |
|---|---|
| Zekuan Xu | 1 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 1 |
| Register | Tegafur trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tegafur works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tegafur (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.